Literature DB >> 10069457

Resistance to mammary tumorigenesis in Copenhagen rats is associated with the loss of preneoplastic lesions.

J E Korkola1, M C Archer.   

Abstract

The resistance of Copenhagen (Cop) rats to mammary tumor development has recently been linked to three loci, but the genes have yet to be cloned and the mechanism of resistance is still largely unknown. In order to determine the cellular events associated with resistance, we prepared mammary whole mounts from Cop and susceptible Wistar Furth (WF) rats 0, 15, 30, 45 and 60 days after treatment with 50 mg/kg N-methyl-N-nitrosourea (MNU). At 15 days, treated rats of both strains had significantly more undifferentiated structures [terminal end buds (TEBs)] and significantly fewer differentiated structures [alveolar buds (ABs)] than untreated rats. Treated Cop rats, however, had significantly more TEBs and fewer ABs than age-matched, treated WF rats. Histological analysis of preneoplastic lesions tentatively identified from the whole mounts showed that like WF rats, Cop rats developed early preneoplastic lesions [intraductal proliferations (IDPs)] by 15 days post-MNU treatment. Unlike IDPs from WF rats, however, the IDPs in Cop rats then decreased in number until they were absent 60 days post-MNU treatment. Furthermore, they failed to progress into more advanced lesions such as ductal carcinomas in situ (DCIS). Finally, we found G-->A activating mutations in codon 12 of the Ha-ras gene in 60% of IDPs from Cop rats and 75% of IDPs from WF rats. Our results show that resistance in Cop rats is not due to a target cell population for the carcinogen that is smaller than in susceptible rats or to the failure of the carcinogen to inhibit mammary gland differentiation. Furthermore, we have shown that Cop rats develop preneoplastic IDPs that harbor Ha-ras mutations but, unlike IDPs in susceptible strains, they fail to progress and ultimately disappear.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069457     DOI: 10.1093/carcin/20.2.221

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Genetic identification of distinct loci controlling mammary tumor multiplicity, latency, and aggressiveness in the rat.

Authors:  Xiaojiang Quan; Jean-François Laes; Daniel Stieber; Michèle Rivière; Jose Russo; Dirk Wedekind; Wouter Coppieters; Frédéric Farnir; Michel Georges; Josiane Szpirer; Claude Szpirer
Journal:  Mamm Genome       Date:  2006-04-04       Impact factor: 2.957

Review 2.  Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.

Authors:  James L Miller; Arianna P Bartlett; Rebecca M Harman; Prabin Dhangada Majhi; D Joseph Jerry; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-07-29       Impact factor: 2.698

Review 3.  Rat models of premalignant breast disease.

Authors:  H J Thompson; M Singh
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 4.  Mammary cancer susceptibility: human genes and rodent models.

Authors:  Claude Szpirer; Josiane Szpirer
Journal:  Mamm Genome       Date:  2007-12-01       Impact factor: 2.957

5.  Cyclin D1 expression during rat mammary tumor development and its potential role in the resistance of the Copenhagen rat.

Authors:  J E Korkola; G A Wood; M C Archer
Journal:  Breast Cancer Res       Date:  1999-10-07       Impact factor: 6.466

6.  Susceptibility to N-methyl-N-nitrosourea-induced retinal degeneration in different rat strains.

Authors:  Yuko Emoto; Katsuhiko Yoshizawa; Yuichi Kinoshita; Michiko Yuki; Takashi Yuri; Airo Tsubura
Journal:  J Toxicol Pathol       Date:  2015-11-20       Impact factor: 1.628

Review 7.  Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast.

Authors:  Jessica S Helm; Ruthann A Rudel
Journal:  Arch Toxicol       Date:  2020-05-13       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.